1. ^{{Cite web | url=http://www.usada.org/substances/effects-of-performance-enhancing-drugs/ | title=Effects of Performance-Enhancing Drugs | USADA}}
2. ^[https://dash.harvard.edu/handle/1/8848246 Anon. Better Fighting Through Chemistry? The Role of FDA Regulation in Crafting the Warrior of the Future.] Food and Drug Law: Final Paper. March 8, 2004.
3. ^{{cite web|url=http://www.vanderbilt.edu/AnS/psychology/health_psychology/caffeine_sports.htm |title=Caffeine and Sports Performance |publisher=Vanderbilt.edu |date= |accessdate=2012-03-04}}
4. ^{{cite web|url=https://www.drugabuse.gov/publications/research-reports/anabolic-steroid-abuse/what-are-anabolic-steroids |title=What are anabolic steroids?|date=August 2006 |accessdate=2016-04-11 |publisher=National Institute on Drug Abuse}}
5. ^{{cite web|last=McKelvey Martin|first=Valerie|title=Drugs in Sport|url=http://www.ulster.ac.uk/scienceinsociety/drugsinsport.html|accessdate=15 April 2013}}
6. ^{{cite journal |vauthors=Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD |title=Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit |journal=Journal of Medicinal Chemistry |volume=52 |issue=12 |pages=3597–617 |date=June 2009 |pmid=19432422 |doi=10.1021/jm900280m |url=}}
7. ^Drug Enforcement Administration. November 2013 Clenbuterol
8. ^{{cite journal | pmid = 21142283 | doi=10.2165/11537540-000000000-00000 | volume=41 | issue=1 | title=β₂-Agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials | date=January 2011 | journal=Sports Med | pages=39–57 | vauthors=Pluim BM, de Hon O, Staal JB et al}}
9. ^¹ {{cite journal | vauthors = Pesta DH, Angadi SS, Burtscher M, Roberts CK | title = The effects of caffeine, nicotine, ethanol, and tetrahydrocannabinol on exercise performance | journal = Nutr Metab (Lond) | volume = 10 | issue = 1 | pages = 71 | year = 2013 | pmid = 24330705 | pmc = 3878772 | doi = 10.1186/1743-7075-10-71 | quote = Caffeine-induced increases in performance have been observed in aerobic as well as anaerobic sports (for reviews, see [26,30,31]). Trained athletes seem to benefit from a moderate dose of 5 mg/kg [32], however, even lower doses of caffeine (1.0–2.0 mg/kg) may improve performance [33]. Some groups found significantly improved time trial performance [34] or maximal cycling power [35], most likely related to a greater reliance on fat metabolism and decreased neuromuscular fatigue, respectively. Theophylline, a metabolite of caffeine, seems to be even more effective in doing so [36]. The effect of caffeine on fat oxidation, however, may only be significant during lower exercise intensities and may be blocked at higher intensities [37]. ... For both caffeine-naïve as well as caffeine-habituated subjects, moderate to high doses of caffeine are ergogenic during prolonged moderate intensity exercise [61]. ... In summary, caffeine, even at physiological doses (3–6 mg/kg), as well as coffee are proven ergogenic aids and as such – in most exercise situations, especially in endurance-type events – clearly work-enhancing [26]. It most likely has a peripheral effect targeting skeletal muscle metabolism as well as a central effect targeting the brain to enhance performance, especially during endurance events (see Table 1). Also for anaerobic tasks, the effect of caffeine on the CNS might be most relevant. ... Muendel et al. [93] found a 17% improvement in time to exhaustion after nicotine patch application compared to a placebo without affecting cardiovascular and respiratory parameters or substrate metabolism. In this sense, nicotine seems to exert similar effects as caffeine by delaying the development of central fatigue as impaired central drive is an important factor contributing to fatigue during exercise. ... The physiological effects of the above mentioned substances are well established. However, the ergogenic effect of some of the discussed drugs may be questioned and one has to consider the cohort tested for every specific substance. However, only caffeine has enough strength of evidence to be considered an ergogenic aid.}}
10. ^^1 2 3 {{cite journal |vauthors=Liddle DG, Connor DJ | title = Nutritional supplements and ergogenic Aids | journal = Prim. Care | volume = 40 | issue = 2 | pages = 487–505 |date=June 2013 | pmid = 23668655 | doi = 10.1016/j.pop.2013.02.009 |quote= Amphetamines and caffeine are stimulants that increase alertness, improve focus, decrease reaction time, and delay fatigue, allowing for an increased intensity and duration of training ...
Physiologic and performance effects [of amphetamines]
{{•}}Amphetamines increase dopamine/norepinephrine release and inhibit their reuptake, leading to central nervous system (CNS) stimulation
{{•}}Amphetamines seem to enhance athletic performance in anaerobic conditions 39 40
{{•}}Improved reaction time
{{•}}Increased muscle strength and delayed muscle fatigue
{{•}}Increased acceleration
{{•}}Increased alertness and attention to task}}
11. ^^1 2 {{cite journal |author=Parr JW |title=Attention-deficit hyperactivity disorder and the athlete: new advances and understanding |journal=Clin. Sports Med. |volume=30 |issue=3 |pages=591–610 |date=July 2011 |pmid=21658550 |doi=10.1016/j.csm.2011.03.007 |quote=In 1980, Chandler and Blair⁴⁷ showed significant increases in knee extension strength, acceleration, anaerobic capacity, time to exhaustion during exercise, pre-exercise and maximum heart rates, and time to exhaustion during maximal oxygen consumption (VO2 max) testing after administration of 15 mg of dextroamphetamine versus placebo. Most of the information to answer this question has been obtained in the past decade through studies of fatigue rather than an attempt to systematically investigate the effect of ADHD drugs on exercise. ... In 2008, Roelands and colleagues⁵³ studied the effect of reboxetine, a pure NE reuptake inhibitor, similar to atomoxetine, in 9 healthy, well-trained cyclists. They too exercised in both temperate and warm environments. They showed decreased power output and exercise performance at both 18 and 30 degrees centigrade. Their conclusion was that DA reuptake inhibition was the cause of the increased exercise performance seen with drugs that affect both DA and NE (MPH, amphetamine, and bupropion).}}
12. ^^1 2 {{cite journal |vauthors=Parker KL, Lamichhane D, Caetano MS, Narayanan NS | title = Executive dysfunction in Parkinson's disease and timing deficits | journal = Front. Integr. Neurosci. | volume = 7 | page = 75 | date = October 2013 | pmid = 24198770 | pmc = 3813949 | doi = 10.3389/fnint.2013.00075 | quote = Manipulations of dopaminergic signaling profoundly influence interval timing, leading to the hypothesis that dopamine influences internal pacemaker, or “clock,” activity. For instance, amphetamine, which increases concentrations of dopamine at the synaptic cleft advances the start of responding during interval timing, whereas antagonists of D2 type dopamine receptors typically slow timing;... Depletion of dopamine in healthy volunteers impairs timing, while amphetamine releases synaptic dopamine and speeds up timing. }}
13. ^¹ {{cite journal |vauthors=Roelands B, de Koning J, Foster C, Hettinga F, Meeusen R | title = Neurophysiological determinants of theoretical concepts and mechanisms involved in pacing | journal = Sports Med. | volume = 43 | issue = 5 | pages = 301–311 |date=May 2013 | pmid = 23456493 | doi = 10.1007/s40279-013-0030-4 }}
14. ^¹ {{cite journal | vauthors = Rattray B, Argus C, Martin K, Northey J, Driller M | title = Is it time to turn our attention toward central mechanisms for post-exertional recovery strategies and performance? | journal = Front. Physiol. | volume = 6 | issue = | pages = 79 | date = March 2015 | pmid = 25852568 | pmc = 4362407 | doi = 10.3389/fphys.2015.00079 | quote = Aside from accounting for the reduced performance of mentally fatigued participants, this model rationalizes the reduced RPE and hence improved cycling time trial performance of athletes using a glucose mouthwash (Chambers et al., 2009) and the greater power output during a RPE matched cycling time trial following amphetamine ingestion (Swart, 2009). ... Dopamine stimulating drugs are known to enhance aspects of exercise performance (Roelands et al., 2008)}}
15. ^¹ {{cite journal | vauthors = Roelands B, De Pauw K, Meeusen R | title = Neurophysiological effects of exercise in the heat | journal = Scand. J. Med. Sci. Sports | volume = 25 Suppl 1 | issue = | pages = 65–78 | date = June 2015 | pmid = 25943657 | doi = 10.1111/sms.12350 | quote = Physical fatigue has classically been attributed to peripheral factors within the muscle (Fitts, 1996), the depletion of muscle glycogen (Bergstrom & Hultman, 1967) or increased cardiovascular, metabolic, and thermoregulatory strain (Abbiss & Laursen, 2005; Meeusen et al., 2006b). In recent decennia however, it became clear that the central nervous system plays an important role in the onset of fatigue during prolonged exercise (Klass et al., 2008), certainly when ambient temperature is increased ... 5-HT, DA, and NA have all been implicated in the control of thermoregulation and are thought to mediate thermoregulatory responses, certainly since their neurons innervate the hypothalamus (Roelands & Meeusen, 2010). ... This indicates that subjects did not feel they were producing more power and consequently more heat. The authors concluded that the “safety switch” or the mechanisms existing in the body to prevent harmful effects are overridden by the drug administration (Roelands et al., 2008b). Taken together, these data indicate strong ergogenic effects of an increased DA concentration in the brain, without any change in the perception of effort. ... The combined effects of DA and NA on performance in the heat were studied by our research group on a number of occasions. ... the administration of bupropion (DA/NA reuptake inhibitor) significantly improved performance. Coinciding with this ergogenic effect, the authors observed core temperatures that were much higher compared with the placebo situation. Interestingly, this occurred without any change in the subjective feelings of thermal sensation or perceived exertion. Similar to the methylphenidate study (Roelands et al., 2008b), bupropion may dampen or override inhibitory signals arising from the central nervous system to cease exercise because of hyperthermia, and enable an individual to continue maintaining a high power output}}
16. ^{{cite journal | vauthors = Buford TW, Kreider RB, Stout JR, Greenwood M, Campbell B, Spano M, Ziegenfuss T, Lopez H, Landis J, Antonio J | title = International Society of Sports Nutrition position stand: creatine supplementation and exercise | journal = J Int Soc Sports Nutr | volume = 4 | issue = | pages = 6 | year = 2007 | pmid = 17908288 | pmc = 2048496 | doi = 10.1186/1550-2783-4-6 | url = }}
17. ^^1 2 3 {{cite journal | vauthors = Momaya A, Fawal M, Estes R | title = Performance-enhancing substances in sports: a review of the literature | journal = Sports Med. | volume = 45 | issue = 4 | pages = 517–531 | date = April 2015 | pmid = 25663250 | doi = 10.1007/s40279-015-0308-9 | quote = }}
18. ^{{cite journal|last1=Koncic|first1=MZ|last2=Tomczyk|first2=M|title=New insights into dietary supplements used in sport: active substances, pharmacological and side effects.|journal=Current Drug Targets|date=August 2013|volume=14|issue=9|pages=1079–92 |pmid=23574283 |url=https://www.researchgate.net/publication/236190823|doi=10.2174/1389450111314090016}}
19. ^{{cite web|title=Reflection Paper on the Adaptogenic Concept |url=http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003646.pdf|publisher=European Medicines Agency Committee on Herbal Medicinal Products|date=8 May 2008}}
20. ^¹ {{cite journal | vauthors = Frati P, Kyriakou C, Del Rio A, Marinelli E, Vergallo GM, Zaami S, Busardò FP | title = Smart drugs and synthetic androgens for cognitive and physical enhancement: revolving doors of cosmetic neurology | journal = Curr Neuropharmacol | volume = 13 | issue = 1 | pages = 5–11 | date = January 2015 | pmid = 26074739 | pmc = 4462043 | doi = 10.2174/1570159X13666141210221750 | quote = Cognitive enhancement can be defined as the use of drugs and/or other means with the aim to improve the cognitive functions of healthy subjects in particular memory, attention, creativity and intelligence in the absence of any medical indication. ... The first aim of this paper was to review current trends in the misuse of smart drugs (also known as Nootropics) presently available on the market focusing in detail on methylphenidate, trying to evaluate the potential risk in healthy individuals, especially teenagers and young adults.}}
21. ^{{cite journal | vauthors = Ilieva IP, Hook CJ, Farah MJ | title = Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis | journal = J. Cogn. Neurosci. | volume = 27| issue = 6| pages = 1069–89 | date = January 2015 | pmid = 25591060 | doi = 10.1162/jocn_a_00776 | quote = The present meta-analysis was conducted to estimate the magnitude of the effects of methylphenidate and amphetamine on cognitive functions central to academic and occupational functioning, including inhibitory control, working memory, short-term episodic memory, and delayed episodic memory. In addition, we examined the evidence for publication bias. Forty-eight studies (total of 1,409 participants) were included in the analyses. We found evidence for small but significant stimulant enhancement effects on inhibitory control and short-term episodic memory. Small effects on working memory reached significance, based on one of our two analytical approaches. Effects on delayed episodic memory were medium in size. However, because the effects on long-term and working memory were qualified by evidence for publication bias, we conclude that the effect of amphetamine and methylphenidate on the examined facets of healthy cognition is probably modest overall. In some situations, a small advantage may be valuable, although it is also possible that healthy users resort to stimulants to enhance their energy and motivation more than their cognition. ... Earlier research has failed to distinguish whether stimulants’ effects are small or whether they are nonexistent (Ilieva et al., 2013; Smith & Farah, 2011). The present findings supported generally small effects of amphetamine and methylphenidate on executive function and memory. Specifically, in a set of experiments limited to high-quality designs, we found significant enhancement of several cognitive abilities. ...

The results of this meta-analysis cannot address the important issues of individual differences in stimulant effects or the role of motivational enhancement in helping perform academic or occupational tasks. However, they do confirm the reality of cognitive enhancing effects for normal healthy adults in general, while also indicating that these effects are modest in size.| url = https://repository.upenn.edu/neuroethics_pubs/130 }}
22. ^{{cite web|title=Performance-Enhancing Drug Resources|url=http://www.drugfreesport.com/drug-resources/performance-enhancing-drugs-steroids.asp|publisher=Drug Free Sport|accessdate=14 April 2013}}
23. ^{{Cite web|title = Who we are|url = https://www.wada-ama.org/en/who-we-are|website = World Anti-Doping Agency|accessdate = 2015-11-03|date = 2013-11-14}}
24. ^{{Cite web|title = U.S. Anti-Doping Agency – USADA|url = http://www.usada.org/|website = U.S. Anti-Doping Agency (USADA)|accessdate = 2015-11-03}}